A Highly Selective Humanized DDR1 mAb Reverses Immune Exclusion by Disrupting Collagen Fiber Alignment in Breast Cancer | May 26, 2023
AACR Poster Presentation – High Prevalence of Immune exclusion in Cancer as Determined by Pathologist Assessment and Image Analysis | April 17-18, 2023
SITC 2022 Conference – Discoidin Domain Receptor 1 Expression is Associated with Stroma TGF-beta Signaling in Selected Cancers | November 10, 2022
View More Presentations and Publications
June 22, 2023 | Parthenon Therapeutics Announces Publication in Journal for ImmunoTherapy of Cancer on the Role of PRTH-101 Inhibiting DDR1 in Immune Excluded Tumors
June 12, 2023 | Parthenon Therapeutics Announces Publication in Journal for ImmunoTherapy of Cancer on the Role of Immune Exclusion in Cancer
April 25, 2023 | Parthenon Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of PRTH-101, a Novel DDR1 Inhibitor for the Treatment of Immune-Excluded Solid Tumors
View More News
